App-Quantinova.ai

Correlation between progression free survival and overall survival in patients with metastatic breast cancer receiving anthracyclines, taxanes or targeted therapies: A trial level meta-analysis.

Georges Adunlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

New threshold of ER positivity in early stage HER2- breast cancer.

Takeo Fujii - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes.

Neelima Vidula - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Androgen Tear

The association of age with breast cancer mortality within four race/ethnicities for the triple negative and HER2-overexpressing subtypes.

Carol Parise - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC).

Renata Duchnowska - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A phase 1 window of opportunity study of valproic acid (VPA) in breast cancer testing a gene expression biomarker.

Adam Louis Cohen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Valproic Acid

Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.

Naoko Matsuda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).

Aditya Bardia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Seviteronel

BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.

Kerstin Rhiem - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.

Sergey Klimov - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.

Sergey Klimov - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.

Michael J. Hall - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

TP53

Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.

Shoshana M. Rosenberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Features of the metabolic syndrome and survival after a diagnosis of breast cancer in the Womens Health Initiative (WHI).

Jennifer Lynn Beebe-Dimmer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Locoregional relapse in BRCA1/2 breast cancer women treated with breast-conserving surgery.

Maria Jose Juan Fita - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.

Yeh Chen Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Risk of HER2-positive breast cancer among germline CHEK2 mutation carriers with breast cancer.

Chethan Ramamurthy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Association of male breast cancer and prostate cancer: A large population based study.

Shaheenah S. Dawood - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Breast cancer chemoprevention in primary care: Assessing readiness for change.

Haiyun Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Methadone hydrochloride

Risk of male breast cancer in users of testosterone 5 reductase inhibitors.

Hakan Lars Olsson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Filters

14023 Abstracts